Quantcast

Clovis Oncology (CLVS) Surges: Stock Moves 5.9% Higher


Shutterstock photo

Clovis Oncology, Inc. CLVS was a big mover last session, as the company saw its shares rise nearly 6% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This reverses the recent trend for the company as the stock is now down 10.6% in the past one-month time frame.

The stock gained after the company received the FDA's extended approval for its drug in ovarian cancer, Rubraca.

The company has seen one negative estimate revision in the past few months, while its Zacks Consensus Estimate for the current quarter has also moved lower over the past few months, suggesting there may be trouble down the road. So make sure to keep an eye on this stock going forward, to see if this recent move higher can last.

Clovis Oncology currently has a Zacks Rank #4 (Sell) while its Earnings ESP is 0.00%.  

Clovis Oncology, Inc. Price

Clovis Oncology, Inc. Price | Clovis Oncology, Inc. Quote

A better-ranked stock in the Medical - Biomedical and Genetics industry is Ligand Pharmaceuticals Incorporated LGND , which currently carries a Zacks Rank #1 (Strong Buy). You can see  the complete list of today's Zacks #1 Rank stocks here .

Is CLVS going up? Or down? Predict to see what others think: Up or Down

Zacks Editor-in-Chief Goes "All In" on This Stock

Full disclosure, Kevin Matras now has more of his own money in one particular stock than in any other. He believes in its short-term profit potential and also in its prospects to more than double by 2019. Today he reveals and explains his surprising move in a new Special Report.

Download it free >>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Ligand Pharmaceuticals Incorporated (LGND): Free Stock Analysis Report

Clovis Oncology, Inc. (CLVS): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.



This article appears in: Investing , Investing Ideas , Stocks
Referenced Symbols: LGND , CLVS


More from Zacks.com

Subscribe






Zacks.com
Contributor:

Zacks.com

Equity Research








Research Brokers before you trade

Want to trade FX?